<![CDATA[Pembrolizumab Monotherapy Improves PFS in Frontline dMMR Endometrial Cancer]]>
Phase 3positivePembrolizumabPositive
AI Analysis
Summary
The phase 3 KEYNOTE-C93 trial demonstrated that pembrolizumab monotherapy improved progression-free survival compared to chemotherapy in patients with dMMR advanced or recurrent endometrial cancer, meeting its primary endpoint.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary endpoint of PFS with pembrolizumab monotherapy vs chemotherapy
Importance:8/10
Sentiment:
0.85
Phase 3OncologyImmunotherapyEndometrial CancerPositive Data
Related Companies
Read the original article
Published by Cancer Network on July 16, 2026 3:30 PM